Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Budesonide for Maintenance Treatment of Collagenous Colitis

This study has been completed.
Information provided by:
Technische Universität Dresden Identifier:
First received: September 9, 2005
Last updated: March 29, 2010
Last verified: March 2010

The purpose of this study is to determine whether orale budesonide is effective in maintaining clinical remission in patients with collagenous colitis.

Condition Intervention Phase
Collagenous Colitis
Drug: Budesonide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Budesonide in Maintenance Treatment of Collagenous Colitis

Resource links provided by NLM:

Further study details as provided by Technische Universität Dresden:

Primary Outcome Measures:
  • Proportion of patients in clinical remission after 6 months

Secondary Outcome Measures:
  • time to relapse
  • safety
  • quality of life
  • histological improvement

Estimated Enrollment: 75
Study Start Date: July 2004
Estimated Study Completion Date: March 2008
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to determine whether orale budesonide is effective in maintaining clinical remission in patients with collagenous colitis.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • collagenous colitis
  • diarrhea
  • written informed consent

Exclusion Criteria:

  • infectious causes for diarrhea
  • other inflammatory bowel diseases
  • history of colonic surgery
  • celiac disease
  • malignancies
  • severe concomitant diseases
  • use of budesonide, steroids, mesalazine within the previous 2 weeks
  • known intolerance to budesonide
  • history of lack of response to budesonide
  • pregnancy,lactation
  • drug and/or alcohol abuse
  • lack of compliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180076

Medical Department I, Technical University Hospital
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Principal Investigator: Stephan Miehlke, Prof. Medical Department I, Technical University Hospital, Dresden, Germany
  More Information

No publications provided Identifier: NCT00180076     History of Changes
Other Study ID Numbers: MIMIC
Study First Received: September 9, 2005
Last Updated: March 29, 2010
Health Authority: Germany: Federal Institute for Drugs and Medicinal Device

Keywords provided by Technische Universität Dresden:
collagenous colitis
microscopic colitis

Additional relevant MeSH terms:
Colitis, Collagenous
Colitis, Microscopic
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on March 03, 2015